
    
      Treatment with pembrolizumab will continue for a maximum of 35 administrations (approximately
      2 years) or until documented disease progression by investigator assessment, unacceptable
      adverse event(s) (AEs), intercurrent illness that prevents further administration of
      treatment, participant withdraws consent, pregnancy of the participant, noncompliance with
      study treatment or procedure requirements, or administrative reasons.
    
  